Clinical Trial

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

Terminated Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
Sponsor decision
Summary
A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard of Care Alone in Patients with Overt Hepatic Encephalopathy
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-05-16; most recent amendment 2026-01-09.
Status change: Recruiting → Terminated 2025-10-15
Status change: Not Yet Recruiting → Recruiting 2025-09-25
Trial Details
NCT Number NCT06987968
Lead Sponsor Genfit
Conditions Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
Enrollment 3 participants
Start Date 2025-08-25
Primary Completion 2025-09-08 (estimated)
Study Completion 2025-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-12